Related Experiment Video
Updated: Mar 27, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
[New viral risks in blood transfusion by 2016]
1EA3064, Groupe immunité des muqueuses et agents pathogènes (GIMAP), faculté de médecine de Saint-Étienne, université de Lyon, 42023 Saint-Étienne, France; Laboratoire des agents infectieux et d'hygiène, hôpital Nord, CHU de Saint-Étienne, 42055 Saint-Étienne, France.
Viral safety in blood transfusions is a growing concern due to emerging viruses like Hepatitis E and new Flaviviridae members. Enhanced pathogen inactivation methods are urgently needed to ensure transfusion safety.
Area of Science:
- Virology
- Transfusion Medicine
- Public Health
Background:
- Viral safety is a critical concern in blood product transfusion.
- Despite advancements, the spectrum of transfusion-transmissible viruses continues to expand.
- Previous reviews highlighted existing viral threats, necessitating an update.
Purpose of the Study:
- To update the understanding of viral threats in blood transfusion.
- To detail emerging and potential viral risks identified since 2011.
- To emphasize the need for improved infectious agent inactivation in blood products.
Main Methods:
- Literature review of recent scientific publications and reports.
- Analysis of emerging viral pathogens relevant to transfusion medicine.
- Synthesis of data on viral transmission, prevalence, and risk assessment.
Main Results:
- Hepatitis E virus (HEV) transmission via transfusion is a significant concern.
- Transfusion-transmitted arboviruses pose a variable, region-dependent risk.
- Ebola virus outbreaks highlighted transfusion risks during epidemics.
- Marseillevirus presents a debated, potential latent threat.
- A novel Flaviviridae virus has been identified in blood donors.
Conclusions:
- Emerging viruses like HEV and novel Flaviviridae increase transfusion risks.
- The continuous emergence of viral threats necessitates advanced safety measures.
- Urgent implementation of infectious agent inactivation technologies in blood products is crucial.
More Related Videos
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
11:08Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
Published on: April 8, 2012
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Viral Recombination
Rh Blood Group
Cytomegalovirus Disease
Viral Mutations